Perelman School of Medicine at the University of Pennsylvania

Clinical Cell and Vaccine Production Facility (CVPF)


Current Clinical Trials

All Open Trials | Open Cancer Trials | Open HIV Trials

Title Trial ID# Disease Indication Cell-Biologic Product Principal Investigator
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia (NCT02650414) 15CT055 Pediatric ALL Autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) Stephan Grupp, MD, PhD
Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T cells (huCART19) for Very High-Risk Subsets of B cell Acute Lymphoblastic Leukemia (B-ALL) (NCT03792633) 18CT014 Pediatric ALL huCART19 Shannon Maude, MD, PhD
Phase 1 Study of Human Chimeric Antigen Receptor Modified T Cells in Patients with Mesothelin Expressing Cancers (NCT03054298) UPCC02916 Mesothelin expressing cancers huCART-MESO Janos Tanyi, MD, PhD
Phase 1 Clinical Trial of Adoptive Transfer of Autologous Folate Receptor – Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03585764) UPCC03818 Ovarian Cancer Powell Alpha Folate Receptor MOV19 Dr. Payal Shah
Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination with VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer (NCT05057715) UPCC03821 Ovarian and Pancreatic Cancers huCART-MESO + VCN-01 Janos Tanyi, MD, PhD
Pilot Study of Mature Dendritic Cell Vaccination Against Mutated KRAS in Patients With Resectable Pancreatic Cancer (NCT03592888) UPCC04218 Pancreatic Cancer Dendritic cells Mark O’Hara, MD
Phase 1 Study of Human Chimeric Antigen Receptor Modified T Cells in Patients with Pancreatic Cancer (NCT03323944) UPCC14217 Pancreatic Cancer huCART-MESO Mark O'Hara, MD
Pilot Study of Mature Dendritic Cell Vaccination for Resected Hypermutated Colorectal Cancer (NCT03730948) UPCC16218 Colorectal Cancer Dendritic Cells Kim Reiss-Binder, MD
Mature Dendritic Cell Vaccination Against Mutated Antigens in Patients With Advanced Melanoma (NCT03092453) UPCC17616 Melanoma Pulsed Dendritic Cells Gerald Linette, MD
Phase 1 study of PSMA-TGFBRDN CAR modified T cells in patients with advanced castrate resistant prostate cancer (NCT03089203) UPCC32816 Prostate Cancer PSMA-dnTGFbR CAR Naomi Haas, MD
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Pediatric Subjects With Refractory or Relapsed Acute Myeloid Leukemia (NCT04678336) 19CT011 Acute Myeloid Leukemia CART123 Richard Aplenc, MD, PhD, MSCE

Phase 2 Trial of CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T cells (CART19) for Orphan Indications of Pediatric B cell Acute Lymphoblastic Leukemia (B-ALL) (NCT04276870)

19CTO23 Orphan Indications mCART19

Amanda DiNofia, MD

Phase I Trial of huCART19-IL18 Cells in Patients With Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT04684563) UPCC15420 NHL, CLL huCART19-IL18  Jakub Svoboda, MD
Phase I Trial of Programmed Allogeneic CRISPR-edited T Cells (PACE) Gene Edited to Eliminate Endogenous TCR, HLA-class I and HLA-class II and Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma (NCT05037669) UPCC27419 ALL, NHL, CLL PACE CART19 Noelle Frey, MD
Phase I Trial of GFRa4 CAR T Cells in Adult Patients with Recurrent or Metastatic Medullary Thyroid Cancer (NCT04877613) UPCC12320 Medullary Thyroid Cancer CART-GFRa4 Roger Cohen, MD